Deutsche Bank AG Invests $2.04 Million in Omnicell, Inc. $OMCL

Deutsche Bank AG acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, Holdings Channel reports. The firm acquired 49,147 shares of the company’s stock, valued at approximately $2,041,000.

Other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its stake in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after purchasing an additional 294 shares during the last quarter. Cerity Partners LLC lifted its position in shares of Omnicell by 4.9% during the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock valued at $345,000 after buying an additional 354 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Omnicell by 1.2% in the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after buying an additional 424 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Omnicell by 0.3% in the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after buying an additional 448 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Omnicell by 1.7% in the 2nd quarter. California State Teachers Retirement System now owns 42,552 shares of the company’s stock worth $1,251,000 after buying an additional 692 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

OMCL opened at $33.08 on Friday. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.50 billion, a P/E ratio of 39.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.98. The firm’s 50-day moving average price is $39.80 and its 200-day moving average price is $39.33.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. Omnicell’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on OMCL. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Finally, Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Omnicell has an average rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.